A
834.55
1.39 (0.17%)
| Previous Close | 833.16 |
| Open | 832.15 |
| Volume | 197,028 |
| Avg. Volume (3M) | 358,860 |
| Market Cap | 51,644,796,928 |
| Price / Earnings (TTM) | 35.71 |
| Price / Earnings (Forward) | 27.47 |
| Price / Sales | 14.83 |
| Price / Book | 8.24 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.39 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | argenx SE | Bullish | Bullish |
AIStockmoo Score
1.5
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 1.50 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.54% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,317.00 (Wells Fargo, 57.81%) | Buy |
| Median | 1,091.00 (30.73%) | |
| Low | 858.00 (Baird, 2.81%) | Hold |
| Average | 1,075.44 (28.87%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 846.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 20 Jan 2026 | 1,317.00 (57.81%) | Buy | 809.64 |
| 16 Dec 2025 | 1,264.00 (51.46%) | Buy | 851.42 | |
| Wedbush | 14 Jan 2026 | 1,000.00 (19.83%) | Buy | 799.33 |
| 14 Nov 2025 | 1,000.00 (19.83%) | Buy | 907.98 | |
| Citigroup | 08 Jan 2026 | 1,091.00 (30.73%) | Buy | 795.57 |
| 17 Nov 2025 | 1,124.00 (34.68%) | Buy | 929.61 | |
| Truist Securities | 08 Jan 2026 | 1,030.00 (23.42%) | Buy | 795.57 |
| Baird | 18 Dec 2025 | 858.00 (2.81%) | Hold | 847.05 |
| RBC Capital | 17 Dec 2025 | 925.00 (10.84%) | Buy | 862.05 |
| Stifel | 11 Dec 2025 | 1,248.00 (49.54%) | Buy | 889.49 |
| JP Morgan | 08 Dec 2025 | 1,100.00 (31.81%) | Buy | 900.76 |
| Morgan Stanley | 04 Dec 2025 | 1,110.00 (33.01%) | Buy | 915.97 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG |
| 12 Jan 2026 | Announcement | argenx Highlights 2026 Strategic Priorities |
| 06 Jan 2026 | Announcement | argenx to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Announcement | argenx Announces Leadership Transition Marking Next Evolution of Growth |
| 15 Dec 2025 | Announcement | argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease |
| 18 Nov 2025 | Announcement | argenx Announces Results of Extraordinary General Meeting of Shareholders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |